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Abstract
Background: The impact of B-type natriuretic peptide (BNP) level on the risk of left atrial appendage (LAA)
thrombus in patients with nonvalvular atrial fibrillation (NVAF) has not been prospectively studied.
Methods: In two academic medical centers, we obtained BNP levels immediately prior to transesophageal
echocardiogram performed to exclude LAA thrombus in patients with NVAF.
Results: Among 261 subjects (mean age 65 ± 12 years; 30 % women) with NVAF, 17 (6.5 %) had LAA thrombus and
85 (32.6 %) had at least mild spontaneous echo contrast (SEC). Mean BNP level was significantly higher in patients
with LAA thrombus [775 ± 678 vs. 384 ± 537, P = 0.001]. Receiver operator characteristics analysis demonstrated that
BNP has a good discriminatory capacity for LAA thrombus (area under the curve, 0.74; 95 % confidence interval [CI],
0.63–0.85; P = 0.001); BNP ≥ 67 pg/mL was 100 % sensitive and 20 % specific for LAA thrombus. Multivariate logistic
regression analysis demonstrated that BNP was not independently associated with LAA thrombus (odds-ratio, 1.05
per 100 pg/mL increment; CI, 0.99–1.12; P = 0.127) after adjusting for CHA2DS2-VASc score; while the latter was
independently associated with LAA thrombus after adjusting for BNP level (odds-ratio, 1.46 per CHA2DS2-VASc
point; CI, 1.09–1.96; P = 0.011). Nonetheless, BNP was associated with SEC in univariate and multivariate analysis,
after adjusting for the CHA2DS2-VASc score, (odds-ratio, 1.08; CI, 1.02–1.14; P = 0.005).
Conclusions: BNP is predictive of SEC. However, it does not provide significant incremental value in the prediction
of LAA thrombus.
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Background
Systemic thromboembolism is a serious complication in
patients with nonvalvular atrial fibrillation (NVAF) [1].
Over the past several years, various types of scoring sys-
tems, such as the CHADS2 and CHA2DS2-VASc scores
have been developed for predicting the risk of embolic
events in NVAF patients [2, 3]. These clinical risk scores
seem to offer a modest discriminatory value for the
individual patients [2]. Biomarkers of myocardial stress
such as B-type natriuretic peptide (BNP) have a large body
of evidence showing association with clinical events and
may help refine risk assessment in NVAF patients [4].
Atrial dysfunction is an established risk factor for
thrombus formation in NVAF patients and BNP has been
shown to originate from dysfunctional and stressed atrial
myocadium in these patients [5–7]. Moreover, elevated
left ventricular filling pressure leads to left atrial blood sta-
sis and thrombus formation, which respectively manifest
on transesophageal echocardiography (TEE) as spontan-
eous echo contrast (SEC) and left atrial appendage (LAA)
thrombus [8–10]. Thus, BNP, a surrogate for left
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ventricular filling pressure, may help identify patients at risk
for left atrial blood stasis and LAA thrombus [11, 12]. In-
deed, in retrospective non-concomitant assessment of BNP
levels and LAA thrombus by TEE, our group has demon-
strated an association between plasma BNP level and the
formation of SEC and LAA thrombi in patients with NVAF,
independent of clinical covariates [13]. The present study
aims to prospectively and concomitantly investigate the
predictive value of BNP level in identifying LAA thrombus
and SEC formation in patients with NVAF.
Methods
Patient population and study design
We prospectively enrolled consecutive adult patients with
NVAF who were referred to undergo TEE to “rule-out”
LAA thrombus at the echocardiography laboratories of
Rush University Medical Center (Chicago, IL) and Ad-
vocate Illinois Masonic Medical Center (Chicago, IL) in
the period between January 7, 2011 and November 14,
2013. Eligible patients underwent plasma BNP level meas-
urement from a blood sample drawn immediately before
the reference TEE.
Patients with valvular atrial fibrillation were excluded;
those were patients with mitral stenosis, mitral regurgita-
tion greater than 2+ in severity (scale, 0–4), or any mitral
valve surgical or percutaneous intervention. Additionally,
patients with complex congenital heart disease and ortho-
topic heart transplantation were excluded. Patients with
isolated aortic valvular disease, aortic valve prosthesis,
and right-sided valvular heart disease were not excluded.
All subjects signed an informed and HIPAA consent prior
to enrollement. The study was funded by an internal re-
search grant and approved by the institutional review
board of each participating institution.
Clinical data
Data including patient demographics, comorbidities, antic-
oagulation status, and antiplatelet use were prospectively
collected prior to the TEE. Atrial fibrillation chronicity
was classified as: 1) paroxysmal, defined as spontaneously
reverting to sinus rhythm within 7 days; 2) persistent, de-
fined as lasting more than 7 days but less than 12 months,
or any atrial fibrillation events terminated by electrical or
chemical cardioversion or radiofrequency ablation within
12 months of onset; or 3) permanent, defined as events
lasting more than 12 months [14]. The CHADS2 score
was calculated from the sum of risk predictors of congest-
ive heart failure, hypertension, age ≥75 years, diabetes
mellitus, stroke or transient ischemic attack; weighing
each risk predictor by “1” except for prior stroke/transient
ischemic attack which was weighed by “2” [2]. The
CHA2DS2-VASc score was calculated from the sum of the
risk factors of congestive heart failure, hypertension, age
65–74 or ≥75 years, diabetes mellitus, stroke/transient
ischemic attack, vascular disease, female gender; weighing
each by “1” except for stroke/transient ischemic attack
and age ≥75 years which were weighed by “2” [3, 15].
Congestive heart failure was defined as a history of
clinical heart failure or left ventricular ejection fraction
(LVEF) < 40 %. Vascular disease was defined as peripheral
arterial disease, complex aortic plaque, or prior myocardial
infarction [3]. The left ventricular end-systolic and end-
diastolic volumes and LVEF were prospectively deter-
mined using the biplane Simpson’s method [16] from a
transthoracic echocardiogram acquired immediately prior
to the reference TEE [16]. The LA volume was measured
using single-plane Simpson’s method in the apical 4 cham-
ber view [16]. The left ventricular mass was calculated
using the Devereux formula [17]. All volume and mass
measurements were indexed to the body surface area.
B-type natriuretic peptide
A blood sample for BNP level was drawn immediately
prior to induction of sedation for the reference TEE.
Blood samples were processed at the respective inpatient
laboratory of the participating institutions. BNP level
was expressed in pg/mL.
Transesophageal echocardiography
TEE studies were performed under moderate or deep
sedation, as clinically appropriate. An expert National
Board of Echocardiography certified echocardiographer,
who was blinded to BNP and clinical data, reviewed all
TEE images to determine the presence or absence of
LAA thrombus, defined as a circumscribed and uniformly
echo-dense intracavitary mass distinct from the underlying
left atrial or LAA endocardium and the pectinate muscles,
and present in more than one imaging plane (Fig. 1a) [18].
LAA sludge, defined as a dynamic gelatinous, precipitous
echodensity, without a discrete mass, present throughout
the cardiac cycle, was categorized as LAA thrombus
[19, 20]. SEC was defined as dynamic “smoke-like” echoes
with the characteristic swirling motion with optimal gain
setting during the entire cardiac cycle (Fig. 1b) and was
classified from 1 to 4 based on the criteria described by
Fatkin et al [21]. Peak LAA emptying velocity at the LAA
orifice was measured using pulsed wave Doppler and aver-
aged over 3–5 beats.
Outcomes
The primary outcome of the study was TEE-identified
LAA thrombus. The secondary outcome was TEE-
identified SEC.
Statistical analysis
The two-tailed Student’s t-test was used to compare normally
distributed continuous variables, which were expressed as
mean± standard deviation. The Mann–Whitney test was
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used to compare skewed data. The chi-square test was
used to compare categorical variables, which were
expressed as frequencies and percentages. The Spearman’s
method was used to evaluate linear correlations.
The receiver operating characteristic (ROC) method-
ology was used to analyze the discriminatory capacity of
BNP and CHA2DS2-VASc score in predicting LAA
thrombus. ROC analyses were expressed as curve plots
and calculated area under the curve (AUC) with 95 %
confidence intervals (CI) and associated P value repre-
senting the likelihood of the null hypothesis (AUC = 0.5).
The association between BNP level (in 100 pg/mL incre-
ments) as main independent variable, and LAA thrombus
or SEC (outcome variable) was analyzed in univariate and
multivariate binary logistic regression models. In multi-
variate binary logistic regression models, we initially ad-
justed for the CHA2DS2-VASc score only, and in separate
models we adjusted for the CHA2DS2-VASc score, LVEF,
and oral anticoagulant use. Due to significant collinearity
between BNP level and LA volume index (Spearman’s r =
0.41; P < 0.001), LA volume index was not included in
multivariate models. Risk was expressed as odds-ratios
(OR) with CI. Goodness-of-fit for multivariate models was
confirmed using Hosmer and Lemeshow test.
All tests were 2-tailed, and a P value <0.05 was consid-
ered statistically significant. PASW-22 software (IBM, Inc.,
Armonk, NY) was used for all data analyses.
Results
A total of 261 patients (mean age, 65 ± 12 years; 30 %
women) with NVAF were prospectively enrolled to undergo
plasma BNP level measured in a blood sample drawn im-
mediately prior to their clinically indicated TEE; 199 (76 %)
were recruited from Rush University Medical Center and
62 (24 %) from Advocate Illinois Masonic Medical Center.
The leading indications for TEE were “ruling-out” LAA
thrombus prior to direct current cardioversion (39 %),
catheter ablation (46 %), or implantation or testing of im-
plantable cardioverter-defibrillator (10 %). At the time of
the TEE, 34 (13 %) subjects were in sinus rhythm; the rest
were in atrial dysrhythmia. Among the study subjects, 17
(6.5 %) had a confirmed LAA thrombus by TEE. Table 1
compares the baseline characteristics of patients with and
without LAA thrombus. Notably, patients with LAA
thrombus had a significantly higher mean CHA2DS2-VASc
and CHADS2 scores (both P values = 0.001), lower mean
LVEF, larger LA volume index, lower mean LAA emptying
velocity, higher prevalence of heart failure, and had a trend
towards higher creatinine levels. Patients with LAA
thrombus had statistically insignificant higher rates of War-
farin usage. Chronicity of NVAF was not different between
patients with versus without LAA thrombus (Table 1).
BNP and LAA Thrombus
Subjects with LAA thrombus had a significantly higher
mean BNP level than those without LAA thrombus
[775 ± 678 vs. 384 ± 537, P = 0.001] (Table 1). Furthermore,
there was a significant stepwise increase (P for trend =
0.002) in the prevalence of LAA thrombus with increasing
BNP level (Fig. 2). As shown in Fig. 3, ROC analysis dem-
onstrated that BNP had a good discriminatory capacity for
LAA thrombus (AUC, 0.74; CI, 0.63–0.85; P = 0.001). BNP
level ≥ 67 pg/mL was 100 % sensitive and 20 % specific for
LAA thrombus, whereas BNP ≥ 100 was 94 % sensitive and
32 % specific and BNP ≥ 500 was 53 % sensitive and 78 %
specific for LAA thrombus. CHA2DS2-VASc score had
similar discriminative capacity (AUC, 0.73; CI, 0.62–0.84;
P < 0.001); a score of ≥1 was 100 % sensitive for LAA
thrombus (Fig. 3).
BNP was associated with LAA thrombus in univariate
analysis (OR, 1.08 per 100 pg/mL increment; CI, 1.02–
1.15; P = 0.010). However, in multivariate logistic regression
Fig. 1 Representative Examples. a, left atrial appendage thrombus (arrow); b, left atrial spontaneous echo contrast. Reproduced from Doukky et al. [29],
with permission
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analysis, adjusting for the CHA2DS2-VASc score, BNP was
not independently associated with LAA thrombus (OR,
1.05 per 100 pg/mL increment; CI, 0.99–1.12; P = 0.127),
while the CHA2DS2-VASc score was independently associ-
ated with LAA thrombus after adjusting for BNP (OR, 1.46
per point; CI, 1.09–1.96; P = 0.011). In the latter model,
BNP level did not seem to provide significant incremental
predictive value (Δχ2 = 2.08, P = 0.149) to the CHA2DS2-
VASc score. In an expanded (over-fitted) multivariate logis-
tic regression analysis model, adjusting for CHA2DS2-VASc
score, LVEF, and oral anticoagulants use, BNP was not
independently predictive of LAA thrombus (OR, 1.04 per
100 pg/mL increment; CI, 0.97–1.12; P = 0.229).
BNP and spontaneous echo contrast
Out of 261 study subjects, 85 (33 %) had at least mild
SEC, including all 17 (100 %) individuals with LAA
thrombus. The CHA2DS2-VASc score was associated with
SEC (OR, 1.44 per 1 point increment; CI, 1.23–1.68; P <
0.001). There were modest but highly significant correla-
tions between the degree of SEC (scale, 0–4) and both the
CHA2DS2-VASc score (Spearman r = 0.29, P < 0.001) and
Table 1 Baseline Characteristics
LAA Thrombus
All Subjects Present Absent P value
N = 261 N = 17 N = 244
Age (years) 65 ± 12 69 ± 10 65 ± 12 0.190
Age≥ 75 years 56 (21) 5 (29) 51 (21) 0.409
Age≥ 65 years 150 (58) 13 (76) 137 (56) 0.101
Female 79 (30) 5 (29) 74 (30) 0.937
Hypertension 196 (75) 15 (88) 181 (74) 0.195
Diabetes mellitus 67 (26) 7 (41) 60 (25) 0.130
Congestive heart failure 102 (39) 13 (76) 89 (36) 0.001
History of stroke or TIA 35 (13) 5 (29) 30 (12) 0.045
Vascular disease 53 (20) 5 (29) 48 (20) 0.334
Dyslipidemia 126 (48) 9 (53) 117 (48) 0.691
BMI (Kg/m2) 31.4 ± 8.5 28 ± 5.7 31.7 ± 8.7 0.091
Creatinine (mg/dL) 1.3 ± 1.1 1.9 ± 1.9 1.2 ± 1.0 0.076*
Warfarin 124 (48) 10 (59) 114 (47) 0.334
NOACs 48 (18) 3 (18) 45 (18) 0.935
Antiplatelet 140 (54) 9 (53) 131 (54) 0.952
CHADS2 score 1.9 ± 1.3 2.9 ± 1.3 1.8 ± 1.3 0.001*
CHA2DS2-VASc Score 3.0 ± 1.8 4.4 ± 1.6 3.0 ± 1.8 0.001*
AF chronicity 0.789
Paroxysmal 67 (26) 5 (29) 62 (25)
Persistent 107 (41) 7 (41) 100 (41)
Permanent 34 (13) 3 (18) 31 (13)
Unknown 53 (20) 2 (12) 51 (21)
LVEF (%) 47 ± 17 34 ± 13 48 ± 17 0.002
LVEDV index (mL/m2) 54 ± 29 69 ± 34 53 ± 29 0.054
LV mass index (g/m2) 103 ± 41 113 ± 29 102 ± 41 0.311
LA volume index (mL/m2) 33 ± 16 42 ± 18 33 ± 16 0.035
Degree of SEC (scale 0–4) 0.6 ± 1.1 3.0 ± 1.1 0.4 ± 0.9 <0.001*
SEC present 85 (33) 17 (100) 68 (28) <0.001
LAA emptying velocity (cm/s) 42 ± 22 25 ± 11 44 ± 22 0.001
BNP (pg/mL) 409 ± 554 775 ± 678 384 ± 537 0.001*
Data presented as mean ± standard deviation or number (%)
TIA transient ischemic attack, BMI body mass Index, NOACs novel oral anticoagulants, AF atrial fibrillation, LVEF Left ventricular ejection fraction, LVEDV left
ventricular end-diastolic volume, LV left ventricular, LA left atrial, SEC spontaneous echo contrast, LAA left atrial appendage, BNP B-type natriuretic peptide,
*Mann–Whitney test
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BNP (Spearman r = 0.32, P < 0.001). In a multivariate lo-
gistic regression analysis model that included BNP level
and the CHA2DS2-VASc score, BNP was independently
predictive of SEC (OR, 1.08 per 100 pg/mL increment; CI,
1.02–1.14; P = 0.005). In this model, the CHA2DS2-VASc
score was also predictive of SEC (OR, 1.35; CI, 1.15–1.59;
P < 0.001). In an expanded logistic regression model, that
included BNP level, CHA2DS2-VASc score, LVEF, and oral
anticoagulant use, BNP was independently predictive of
SEC (OR, 1.09; CI, 1.02–1.15; P = 0.007).
Discussion
This is the first study to prospectively and concomitantly
correlate the BNP level with LAA thrombus and SEC in
patients with NVAF. This study showed that plasma
BNP level was significantly higher in patients with LAA
thrombus than in those without LAA thrombus. Despite
small number of LAA thrombus events, we observed a
stepwise relationship between BNP level (in tertiles) and
risk of LAA thrombus. Thus, BNP level may help in
identifying patients at risk for LAA thrombus. BNP level
was independently predictive of SEC but not of LAA
thrombus.
BNP is a neurohormone secreted from the myocytes
mainly in response to increased wall tension such as vol-
ume or pressure overload and has been shown to be ele-
vated in patients with NVAF [22]. Moreover, BNP has
also been shown to predict future AF [23, 24] and risk of
thromboembolism [13, 25]. Recent studies have shown
BNP to be a valuable marker for general cardiovascular
risk stratification in patients with NVAF [26]. Patho-
physiologically, increased LV filling pressure causes atrial
stretch, which is a well-known reason for development
of NVAF [27]. Loss of effective atrial contraction during
atrial fibrillation coupled with elevation in the left ven-
tricular filling pressure can lead to left atrial blood sta-
sis, manifesting as SEC, and subsequent risk for LAA
thrombus [28, 29]. BNP level correlates with left ventricu-
lar filling pressure (6); thus, it may aid in predicting SEC
and LAA thrombus. Indeed, in a retrospective analysis
of 136 patients with NVAF our group demonstrated an
association between BNP, a surrogate of LV filling pres-
sure, and LAA thrombus and SEC [13]. The study dem-
onstrated that BNP was predictive of LAA thrombus
independent of the CHADS2 and CHA2DS2-VASc scores,
which are known predictors of LAA thrombus and systemic
embolization in NVAF. Additionally, the study showed that
all patients with LAA thrombus had BNP level > 500 pg/mL
[13]. Moreover, in another recent retrospective study of 524
non-anticoagulated NVAF patients, Ochiumi et al., [25]
showed that BNP was an independent predictor of LAA
thrombus, and identified plasma BNP level of 251 pg/mL
as a useful cutoff for predicting LAA thrombus. Notably,
both of the aforementioned studies were limited by
Fig. 2 Prevalence of Left Atrial Appendage Thrombus according to
BNP level
Fig. 3 Receiver Operating Characteristic Curves in Diagnosing LAA
Thrombus. LAA, left atrial appendage; AUC, area under the curve; CI,
confidence intervals
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retrospective design, incidental rather than systematic
BNP level assessment with TEE, and non-concomitant
BNP measurement with TEE.
The present investigation partially validates the finding
of previous retrospective studies, [13, 25] as BNP was
predictive of LAA thrombus only in univariate analysis
but not in multivariate analysis after adjusting for the
CHA2DS2-VASc score. However, BNP was predictive of
SEC in univariate and multivariate analyses. Since SEC is
a surrogate for LAA thrombus formation and thrombo-
embolic events, [30] it is likely that lack of independent
association between BNP and LAA thrombus is due to
small sample size and limited number of events (type II
error). Moreover, the present study demonstrated that
LAA thrombus was present at much lower BNP level
(67 pg/mL) than previously shown [13, 25]. This signifi-
cant difference in the BNP level associated with LAA
thrombus is likely due to the fact that, given our pro-
spective design, BNP levels were collected immediately
prior to the TEE exam, when patients may have been
near euvolemic state; whereas in other studies BNP was
obtained when clinically indicated, at the height of pa-
tients’ symptoms. Moreover, all patients in the present
study had a BNP level measured. This was not the case
in other published studies in which BNP levels were in-
cidentally available among patients who underwent TEE
studies, thus introducing a clear selection bias. There-
fore, the current work is unique in several important as-
pects: 1) this is the only prospective study to investigate
the impact of BNP on the risk of LAA thrombus; 2) the
study was designed to include dual-center data; 3) con-
comitant BNP and TEE assessment; 4) we investigated
consecutively enrolled patients to undergo BNP level
measurement prior to TEE, which eliminates the bias in-
troduced by analyzing patients who happen to have inci-
dental BNP measurement.
The association between BNP and SEC suggests that
elevated left ventricular filling pressure is associated with
left atrial blood stasis manifesting as SEC. This associ-
ation was independent of other factors such as LVEF,
and oral anticoagulants. This finding also support the
findings regarding LAA thrombus since SEC is the pre-
cursor for LAA thrombus formation.
It was notable that 13 patients were found to have
LAA thrombus despite oral anticoagulant use. This ob-
servation likely reflects the recognition of elevated
thromboembolic risk by the treating physician. It also in-
dicates that oral anticoagulants are not fully protective
of LAA thrombus among high risk NVAF patients.
The present investigation has two important clinical
implications: 1) BNP level can be used as a useful pre-
dictor for LAA thrombus and SEC; 2) Patients with very
low BNP levels seem to be at low risk for LAA thrombus
and perhaps systemic embolic events.
The study is limited by a relatively small sample size
and infrequent LAA thrombus events, which impaired
our ability to analyze many covariates within a given
multivariate logistic regression model. However, the
secondary SEC analyses were consistent with the pri-
mary endpoint analyses; thus adding validity to the study
conclusions.
Conclusions
In patients with NVAF, BNP is predictive of SEC inde-
pendent of clinical risk factors encompassed in the
CHA2DS2-VASc score. BNP level can help predicting
LAA thrombus in patients with NVAF, but does not
seem to provide significant incremental predictive value
beyond the CHA2DS2-VASc score.
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